CNS Pharmaceuticals, Inc.
$2.69
▼
-0.68%
2026-04-21 06:08:01
www.cnspharma.com
NCM: CNSP
Explore CNS Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.06 M
Current Price
$2.69
52W High / Low
$34.8 / $2.06
Stock P/E
—
Book Value
$17.25
Dividend Yield
—
ROCE
-241.26%
ROE
-2.96%
Face Value
—
EPS
$-35.75
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.49
Debt / Equity
7.26
Current Ratio
1.98
Quick Ratio
1.98
Forward P/E
-5.59
Price / Sales
—
Enterprise Value
$-5.1 M
EV / EBITDA
0.32
EV / Revenue
—
Rating
None
Target Price
$10
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 2. | IGC Pharma, Inc. | $0.32 | — | $31.52 M | — | -114.73% | -83.34% | $0.5 / $0.24 | $0.09 |
| 3. | Entrada Therapeutics, Inc. | $13.56 | — | $535.6 M | — | -44.74% | -39.13% | $14.49 / $4.93 | $8.5 |
| 4. | Voyager Therapeutics, Inc. | $4.23 | — | $252.11 M | — | -58.41% | -48.29% | $5.55 / $2.65 | $3.32 |
| 5. | Regeneron Pharmaceuticals, Inc. | $753.59 | 17.99 | $79.36 B | 0.5% | 10.23% | 14.86% | $821.11 / $476.49 | $304.65 |
| 6. | Cogent Biosciences, Inc. | $37 | — | $6.05 B | — | -38.16% | -73.7% | $43.73 / $4.12 | $3.4 |
| 7. | CRISPR Therapeutics AG | $57.69 | — | $5.56 B | — | -31.41% | -30.18% | $78.48 / $33.03 | $20.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -5.99 M | -3.25 M | -2.41 M | -4.34 M | -3.2 M | — |
| Net Profit | -5.96 M | -3.22 M | -2.37 M | -4.3 M | -3.18 M | — |
| EPS in Rs | -7.34 | -3.97 | -2.93 | -5.3 | -3.91 | -153.2 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -15.99 M | -14.9 M | -18.87 M | -15.27 M |
| Net Profit | -15.85 M | -14.86 M | -18.85 M | -15.27 M |
| EPS in Rs | -19.53 | -18.31 | -23.23 | -18.82 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.62 M | 8.7 M | 1.7 M | 13.05 M |
| Total Liabilities | 4.1 M | 2.52 M | 6.13 M | 4.92 M |
| Equity | 4.52 M | 6.18 M | -4.43 M | 8.13 M |
| Current Assets | 8.1 M | 8.66 M | 1.59 M | 12.56 M |
| Current Liabilities | 4.1 M | 2.52 M | 6.13 M | 4.92 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.81 M | -17.11 M | -14.14 M | -10.56 M |
| Investing CF | -0.02 M | -0 M | -0 M | -0 M |
| Financing CF | 14.57 M | 23.03 M | 4.64 M | 15.61 M |
| Free CF | -13.83 M | -17.12 M | -14.14 M | -10.56 M |
| Capex | -0.02 M | -0 M | -0 M | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 21.18% | -23.42% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-07-22 | 1:0.0833333 |
| 2025-02-21 | 1:0.02 |
| 2024-06-05 | 1:0.02 |
| 2022-11-29 | 1:0.0333333 |